N=1 After 40

Not run · August 2026

Chlodantane

I considered it as a possible alternative to bromantane, then decided that novelty and preclinical claims did not establish a better human experiment. A personal research decision, not medical advice, prescribing, sourcing guidance, or an instruction to copy.

Decision: I did not run chlodantane. It has no validated human dose, direct human efficacy record, or demonstrated advantage over bromantane, which has already produced a clear personal mood and stress-tolerance signal.

The Decision

Why I considered it

Chlodantane is increasingly described as a faster, broader, or more powerful successor to bromantane. The interesting version of that claim is acute resilience: animal literature describes protection under hypoxia, heat, cold, toxic exposure, and other extreme stressors after a single administration.

Why I passed

The superiority claim is not supported by human comparisons. I could not find a direct human chlodantane study, a validated human dose, or a usable human safety and interaction record. Moving from limited evidence to almost entirely preclinical evidence is not an upgrade simply because the second molecule is newer to the market.

The bromantane comparison

Both molecules contain an adamantane scaffold, but chlodantane is a benzamide and bromantane is an arylamine. That relationship supports comparison; it does not make their pharmacology or dosing interchangeable. Bromantane has limited human research in asthenic disorders and a partly characterized dopaminergic mechanism. Chlodantane does not have equivalent human or mechanistic support.

The personal asymmetry

Bromantane at 50 mg per day produced a clear and stable improvement in my mood regulation and stress tolerance without a noticeable sleep penalty. That gives me a useful personal baseline. Replacing it with chlodantane would trade a known signal for an unvalidated dose and a much larger safety question.

What could reopen the decision

I would reconsider if chlodantane developed credible human pharmacokinetic and dose-finding data, a characterized adverse-event profile, and controlled evidence relevant to mood, stress tolerance, or performance. Vendor anecdotes and claims that it is simply stronger than bromantane would not close those gaps.

Evidence Review

What it is

Chlodantane, also spelled chlodantan and usually coded ADK-910, is N-(adamantan-2-yl)-4-chlorobenzamide. It was developed as a Russian synthetic adaptogen or actoprotector: a compound intended to preserve physical performance under demanding conditions.

What the preclinical evidence says

Russian animal and cell work describes increased resistance to hypoxia, temperature extremes, and toxic stress. Proposed contributions include cell-membrane stabilization, reduced excessive lipid peroxidation, and immunostimulatory activity. A later review states directly that all of the available pharmacology came from animal or cell-culture experiments and that no clinical research had been conducted.

What has been added online

Claims about stronger dopamine support, improved motivation, cognition, mood regulation, or a cleaner stimulant profile are not established by the chlodantane literature I found. They appear to extend bromantane's better-known pharmacology to a related but different molecule. The old descriptions of broader and rapid activity refer to preclinical stress models, not superior outcomes in people.

The human evidence gap

I found no registered ClinicalTrials.gov study for chlodantane, chlodantan, or ADK-910. That leaves no validated oral bioavailability, half-life, therapeutic range, dose-response relationship, interaction profile, or chronic adverse-event record in humans. A familiar bromantane amount cannot be treated as an equivalent chlodantane dose.

The reproductive signal

A rat study using 50 and 500 mg/kg reported dose- and duration-dependent changes in sexual behavior and spermatogenesis. After two months, the high-dose group showed fewer sperm, more immotile and abnormal forms, and reduced spermatogenesis markers. Those doses are too large to predict a human outcome directly, but the findings prevent assuming reproductive neutrality in the absence of human safety data.

Sources